ASH 2021 | Exploiting the metabolic vulnerabilities of MDS stem cells
Daniel Pollyea
• 10 Dec 2021
Progression from low risk to high risk disease in myelodysplastic syndrome (MDS) remains poorly understood. Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, describes the unique metabolic vulnerabilities of MDS stem cells, which similarly exist in adult acute myeloid leukemia (AML). By elucidating changes in metabolic pathways within different stages of the diseases, new targets can be found that can improve response rates in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
